Bravo At Last For GSK As MATINEE Succeeds In COPD
Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.
Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.